Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Overweight rating on the shares. The firm updated estimates following the recent Eylea biosimilar ...

Regeneron (NASDAQ:REGN) shares trended higher pre-market Friday after JPMorgan upgraded the stock to Overweight from Neutral, noting several key catalysts in 2023, including the upcoming launch of ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00 in a report released on Monday ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday ...

Good morning, and once again, welcome to the 40th annual, and unfortunately, second-time virtual JPMorgan Healthcare ... which is Regeneron. Representing Regeneron are the Company's cofounders ...

The JPMorgan Healthcare Conference currently under ... The one company I had my eyes keenly focused on yesterday was Regeneron Pharmaceuticals, whose founder and CEO, Len Schleifer, was nothing ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...